Skip to main content
Premium Trial:

Request an Annual Quote

Benjamin Bulkley, John Thompson, Edwin Moses, Sir Harry Solomon, Malcolm Weir


Invitrogen has appointed Benjamin Bulkley to the position of senior vice president of commercial operations. Bulkley most recently served as vice president of global services for General Electric’s Medical Systems Information Technologies division. Invitrogen has also promoted John Thompson from vice president of corporate development to senior vice president of corporate development.

Inpharmatica has appointed Edwin Moses as non-executive chairman. Moses has been a non-executive director of the company since July 2001. Sir Harry Solomon, the company’s former chairman, will remain a board director. Moses was previously CEO of Oxford Asymmetry International. Malcolm Weir, Inpharmatica CEO, said the company’s recent transition to a drug discovery business model “has brought with it the need for a chairman experienced in the healthcare sector to help management guide the company through the next stage in its evolution.”

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.